Catalogo dei prodotti della ricerca

FERRO, Domenico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.406
EU - Europa 1.134
AS - Asia 422
SA - Sud America 22
AF - Africa 15
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.388
IT - Italia 388
IN - India 197
SE - Svezia 186
UA - Ucraina 165
CN - Cina 139
FI - Finlandia 101
RO - Romania 84
GB - Regno Unito 62
SG - Singapore 51
AT - Austria 36
DE - Germania 36
JO - Giordania 24
IE - Irlanda 23
BG - Bulgaria 22
AR - Argentina 20
CA - Canada 17
TG - Togo 11
BE - Belgio 9
FR - Francia 5
GR - Grecia 4
HK - Hong Kong 4
CH - Svizzera 3
NL - Olanda 3
PL - Polonia 3
TR - Turchia 3
AU - Australia 2
BJ - Benin 2
IR - Iran 2
RU - Federazione Russa 2
BZ - Belize 1
CL - Cile 1
EC - Ecuador 1
EU - Europa 1
MT - Malta 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 6.002
Salva come PNG Salva come JPEG
Città #
Fairfield 773
Woodbridge 427
Houston 321
Chandler 306
Ashburn 291
Seattle 261
Ann Arbor 258
Cambridge 231
Wilmington 219
Rome 152
Princeton 116
Dearborn 113
San Paolo di Civitate 96
Plano 91
Lawrence 84
Fremont 81
Beijing 80
Horia 70
San Diego 69
Jacksonville 67
Boston 53
Millbury 47
Andover 33
Vienna 31
Southend 27
Dublin 23
Boardman 22
Sofia 22
New York 21
Federal 20
Amman 19
Des Moines 19
Norwalk 19
Helsinki 14
Bremen 13
Singapore 13
Toronto 13
Falls Church 11
Lomé 11
Brussels 9
Hefei 9
Pomezia 9
San Mateo 9
Bologna 6
London 6
Nanjing 6
Redwood City 6
Buffalo 5
Guangzhou 5
Hebei 5
Kunming 5
Milan 5
Zarqa 5
Bühl 4
Hong Kong 4
Palermo 4
Sacramento 4
San Jose 4
Baotou 3
Chieti 3
Istanbul 3
Los Angeles 3
Phoenix 3
Tappahannock 3
Torino 3
Trumbull 3
Auburn Hills 2
Berlin 2
Bern 2
Bolzano Vicentino 2
Bulgarograsso 2
Chengdu 2
Duncan 2
Fasano 2
Fiumicino 2
Frankfurt am Main 2
Hassan 2
Hyderabad 2
Larissa 2
Las Vegas 2
Lucca 2
L’Aquila 2
Nanchang 2
Orta di Atella 2
Padova 2
Perugia 2
Pescara 2
Redmond 2
Shenyang 2
Taunton 2
Venticano 2
Warsaw 2
Albano Laziale 1
Arnsberg 1
Atlanta 1
Baie-D'Urfe 1
Bangalore 1
Belize City 1
Bergamo 1
Carbonia 1
Totale 4.731
Salva come PNG Salva come JPEG
Nome #
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 162
Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation. the ARAPACIS study 142
Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia 138
LUPUS ANTICOAGULANT AND THE FIBRINOLYTIC SYSTEM IN YOUNG-PATIENTS WITH STROKE 121
Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation 120
Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia 115
Association between high values of D-dimer and Tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients 97
Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation 97
HYPERFIBRINOLYSIS INCREASES THE RISK OF GASTROINTESTINAL HEMORRHAGE IN PATIENTS WITH ADVANCED CIRRHOSIS 89
null 89
Hemostatic balance in patients with liver cirrhosis. report of a consensus conference 88
Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. 88
Ongoing prothrombotic state in the portal circulation of cirrhotic patients 87
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study 84
Soluble CD154 plasma levels in patients with systemic lupus erythematosus: Modulation by antiphospholipid antibodies 81
Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies 79
Clotting Activation and Hyperfibrinolysis in Cirrhosis: Implication for Bleeding and Thrombosis 78
Clotting activation after transjugular intrahepatic portosystemic stent shunt 78
Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study 78
Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking Vitamin K antagonists 77
Inhibition of tissue-factor-mediated thrombin generation by simvastatin 75
Determinants of enhanced thromboxane biosynthesis in systemic lupus erythematosus. 74
Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy 74
1-YEAR SURVEY OF PATIENTS WITH ADVANCED LIVER-CIRRHOSIS - PROGNOSTIC VALUE OF CLINICAL AND LABORATORY INDEXES IDENTIFIED BY THE COX REGRESSION-MODEL 74
Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study 73
INHIBITION OF TISSUE PLASMINOGEN-ACTIVATOR INHIBITOR BY DEFIBROTIDE IN ATHEROSCLEROTIC PATIENTS 71
Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation 71
Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment 70
THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME 70
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. 70
Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis 69
gp91phox-dependent expression of platelet CD40 ligand 68
Bleeding and thrombosis in cirrhotic patients: What really matters? 67
ANTICOAGULANT ACTIVITY OF ANTICARDIOLIPIN ANTIBODIES 67
Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia 66
A POTENT CHAIN-BREAKING ANTIOXIDANT ACTIVITY OF THE CARDIOVASCULAR DRUG DIPYRIDAMOLE 66
High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia 66
Chocolate enriched by extra virgin olive oil improves endothelial function and oxidative stress in patients with diabetes 64
LIPOPROTEIN (A) AND FIBRINOLYTIC SYSTEM IN LIVER-CIRRHOSIS 63
PREKALLIKREIN AND FACTOR-VII AS PROGNOSTIC INDEXES OF LIVER-FAILURE 63
Antiangiogenic metronomic Chemotherapy and hyperthermia in palliation of advanced cancer. 63
Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis 63
Author reply to comment on "Bleeding and thrombosis in cirrhotic patients: What really matters?" 62
Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state 61
Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia 61
Hepatitis C virus, antiphospholipid antibodies, and thrombosis 61
LUPUS ANTICOAGULANT IN LIVER-CIRRHOSIS 61
Prevalenced of portal vein thrombosis (PVT) and associated factors in cirrhotic patients 61
CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia 60
Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure 59
Endotoxaemia, hyperfibrinolysis, and bleeding in cirrhosis 58
Serum Levels of Vitamin E Are Associated With Early Recurrence of Atrial Fibrillation After Electric Cardioversion 58
CLOTTING ABNORMALITIES IN CHRONIC LIVER-DISEASE 58
Increased thrombin generation and circulating levels of tumour necrosis factor-α in patients with chronic Helicobacter pylori-positive gastritis 57
Added fructose in non-alcoholic fatty liver disease and in metabolic sindrome. a narrative review 56
PREVALENCE OF LUPUS ANTICOAGULANT IN PATIENTS WITH CIRRHOSIS - RELATIONSHIP WITH BETA-2-GLYCOPROTEIN-I PLASMA-LEVELS 56
Evidence for anticoagulant activity and beta2-GPI accumulation in late endosomes of endothelial cells induced by anti-LBPA antibodies. 55
LIPOPROTEIN (A) DOES NOT INFLUENCE HYPERFIBRINOLYSIS IN PATIENTS WITH LIVER-CIRRHOSIS 55
Enhanced soluble Cd40l as predictor of vascular events in patients with non-valvular atrial fibrillation: Results of a prospective study 55
Poor adherence to mediterranean diet and serum lipopolysaccharide are associated with oxidative stress in patients with non-alcoholic fatty liver disease 55
Specificity and sensitivity of diluted aPTT and anticardiolipin antibodies towards thrombosis and miscarriages in patients with systemic lupus erythematosus 55
Fibrinolytic balance and lupus anticoagulant in patients with repeated fetal loss 54
INTERRELATION BETWEEN FACTOR-VII, PREKALLIKREIN, AND HYPERFIBRINOLYSIS IN ADVANCED CIRRHOSIS 53
PREVALENCE OF HYPERFIBRINOLYSIS IN PATIENTS WITH LIVER-CIRRHOSIS 53
Increased thromboxane metabolites excretion in liver cirrhosis 53
Premature coronary disease in systemic lupus 52
Enhanced expression of monocyte tissue factor in patients with liver cirrhosis 52
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients 52
Sex-related differences in the association between metabolic syndrome and gallstone disease 51
Ongoing prothrombotic state in patients with antiphospholipid antibodies: A role for increased lipid peroxidation 50
Coagulopathy of Chronic Liver Disease 50
Statins as Antithrombotic Drugs 49
EVALUATION OF D-DIMER IN PATIENTS WITH LIVER-CIRRHOSIS 48
Antioxidant treatment decreases the titer of circulating anticardiolipin antibodies 48
New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress 48
Vitamin E reduces monocyte tissue factor expression in cirrhotic patients 46
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? 45
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis 45
Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. CALC Group. 44
Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. 42
ARE LOW-LEVEL OF HDL2-CHOLESTEROL A RISK FACTOR FOR ATHEROSCLEROSIS OF CEREBRAL VASCULAR-DISEASE - CASE-REPORT 41
INTRAVASCULAR CLOTTING ACTIVATION AND SYSTEMIC HYPERFIBRINOLYSIS IN PATIENTS WITH SEVERE LIVER-CIRRHOSIS - THE ROLE OF ASCITES 39
Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with wild hypercholesterolemia 39
EFFECT OF ORAL DEFIBROTIDE ON TISSUE-PLASMINOGEN ACTIVATOR AND TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR BALANCE 38
SUCCESSFUL REMOVAL OF ANTIPHOSPHOLIPID ANTIBODIES USING REPEATED PLASMA EXCHANGES AND PREDNISONE 38
Hyperfibrinolysis in liver disease. 2009 Feb;13(1):21-31. 37
Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation 36
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease 35
Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. 35
Enhanced lipid peroxidation in hepatic cirrhosis 34
Ongoing prothrombotic state in patients with antiphospholipid antibodies: A role for increased lipid peroxidation 34
Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. 34
Low-grade endotoxemia and thrombosis in COVID-19 30
Methods for detecting lupus anticoagulant and their relationship to thrombosisand miscarriage in patients with systemic lupus erythematosus 27
null 27
Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelia procoagulant activation 26
Relationship between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver 25
Is the mediterranean diet the best approach to NAFLD treatment today 24
Diet and metabolic syndrome. A narrative review 22
Anticardiolipin antibodies possess anticoagulant activity which is blocked by a monoclonal antibody against a cross reacting idiotype of antiphospholipid antibodies 22
Totale 6.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019473 0 0 0 0 0 0 0 0 0 0 251 222
2019/20201.518 196 51 29 76 153 240 218 180 156 106 75 38
2020/2021768 60 49 27 125 13 103 8 45 61 184 66 27
2021/20221.181 9 77 126 48 129 54 48 110 77 97 189 217
2022/20231.164 236 280 65 126 120 114 8 60 86 16 32 21
2023/2024358 46 55 21 32 29 44 23 27 5 74 2 0
Totale 6.253